Abstract: A dental self-adhesive resin cement is provided comprising a two-component system. A first catalyst component includes one or more acidic monomers. A second base component includes one or more basic fillers. The mixture of the first and second components is polymerizable and has an initial pH that is acidic immediately after mixing and a pH of at least about pH 8 after polymerization.

Abstract: A multi-phase oral composition for whitening teeth.

Abstract: A method for making a toothpaste enabling enamel restoration proposes to encapsulate soluble calcium and phosphate salts within corresponding internal water phases in respective water-in-oil-in-water emulsions. In this way, the soluble calcium and phosphate salts can be present stably in the toothpaste over a long period of time without causing precipitation of calcium phosphate. When the toothpaste of the present disclosure is used in brushing teeth, the water-in-oil-in-water emulsions are ruptured under the effect of friction and pressing, releasing the soluble calcium and/or phosphate salts encapsulated within the corresponding internal water phases. As a result, the liquid in the user's oral cavity will contain high concentrations of calcium and phosphate ions, which can enhance the rate of remineralization of enamel and/or dentin exposed to the oral cavity.

Abstract: The present invention relates to a composition, preferably a cosmetic composition, comprising: (a) at least one oil; (b) at least one polyglyceryl fatty acid ester, preferably with a polyglyceryl moiety derived from 2 to 6 glycerins; (c) at least one compound selected from the group consisting of resorcinol and resorcinol derivatives; and (d) water. The composition according to the present invention can be in the form of a nano- or micro-emulsion, or can have a lamellar structure or a lamellar phase, with better transparency and stability.

Abstract: The present disclosure relates to the field of delivery systems. More particularly, the present disclosure relates to a process for preparing a powdered composition including granules. The granules include at least one active substance present in an encapsulated form and in a non-encapsulated form. They are obtained by drying a mixture including an aqueous phase of a water-soluble polymer, a Pickering emulsion including a non-encapsulated active substance and a microcapsule slurry including an encapsulated active substance that can differ or being the same as the non-encapsulated substance. The disclosure further relates to granules obtained by the process and to products containing them.

Abstract: An oral care composition comprising: (a) arginine, in free or salt form; and (b) zinc oxide and zinc citrate. The oral care composition can reduce or inhibit biofilm formation in an oral cavity.

Abstract: An antimicrobial composition containing: a component (A) that is at least one selected from the group consisting of 1,2-alkanediols having an alkyl group having 6 to 8 carbons and monoalkyl glyceryl ethers having an alkyl group having 6 to 8 carbons; and a component (B) that is at least one selected from the group consisting of tripropylene glycol, 2-methyl-1,3-propanediol, and 3-methyl-1,3-butanediol and a cosmetic containing the antimicrobial composition.

Abstract: An oral care composition, including a mixture of antibacterial agents, the mixture of antibacterial agents including oleanic acid and eugenol at a 2:1 to 3:1 weight ratio.

Abstract: Topical personal care compositions containing amino acids and 4-substituted resorcinols for potentiating glutathione synthesis within skin cells. The compositions can be used to improve skin appearance of chronological aging or photoaging, resulting from exposure to UV light/sunlight, or environmental pollutants. The compositions are also useful for attaining even skin color and reducing pigmentation, age spots and discoloration.

Abstract: The invention relates to a cosmetic composition which comprises: (i) one or more anionic surfactants, (ii) at least 3.5% by weight of one or more fatty acids, relative to the total weight of the composition, and (iii) one or more antidandruff agents, the anionic surfactant(s)/fatty acid(s) weight ratio being from 0.5 to 3.5. The invention also relates to the use of said composition for washing and conditioning the hair.

Abstract: In a cosmetic composition according to the present invention, a coating membrane with a multilayer lamella structure is formed on the outside of ceramide particles by using phytosphingosine, and therefore, the cosmetic composition is stably present without ceramide precipitation even in formulations with low viscosity as well as high viscosity although the particles contain a high content of ceramide, and a cosmetic composition showing an excellent skin barrier recovery effect can be provided.

Abstract: A hair treatment composition comprising (a) from 0.01 to 10 wt % of surfactant in a solvent, by weight of the total composition, and (b) a mixture of amino acids, wherein the mixture of amino acids comprises glutamic acid, alanine and proline gives damage repair benefits to chemically damaged hair.

Abstract: This invention relates to high-water oral care compositions comprising a basic amino acid or salt thereof, together with a precipitated calcium carbonate, glycerol, and to methods of using and of making these compositions.

Abstract: The present invention relates to cochleates using phosphatidylserine/anionic surfactant/calcium chloride and, more specifically, to cochleates comprising phosphatidylserine, an anionic surfactant, calcium chloride, an active ingredient, and water.

Abstract: The present invention discloses a use of neohesperidin or a neohesperidin-containing plant extract in the manufacture of a product for improving and/or promoting skin microcirculation, or for eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation. The present invention also discloses a composition comprising an effective amount of neohesperidin or a neohesperidin-containing plant extract, and to a method for improving and/or promoting skin microcirculation, or eliminating and/or alleviating diseases or conditions associated with poor skin microcirculation, by using neohesperidin. The skin microcirculation of the present invention is preferably eye skin microcirculation.

Abstract: In some embodiments, a composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals. In some embodiments, a composition is disclosed that includes silk fibroin-based protein fragments and is suitable for use in consumer applications. In some embodiments, a preserved composition is disclosed that includes silk fibroin-based protein fragments. In some embodiments, a method of preserving a solution using silk fibroin-based protein fragments is disclosed.

Abstract: Compositions and methods for topical treatment of hair loss in otherwise normal skin that is affected by alopecia are presented. Such compositions include defensins in concentrations that are below those that exhibit antimicrobial activity, and can be in the form of a topically applied gel, lotion, wash, shampoo, cream, or mask. Various formulations for such compositions, which can include various pharmaceutically acceptable stabilizers, emollients, and fragrances, are provided. Such compositions and methods can be used in conjunction with traditional methods for treatment of hair loss.

Abstract: A cosmetic composition is disclosed for applying to skin. The composition includes a liquid and dispersed in the liquid: any amount or form of fucoidan, any amount or form of beta glucan; and any amount of a marine extract. When the cosmetic composition is applied to the skin, the appearance of the skin is improved.

Abstract: Injectable compositions and methods of treating skin can help improve hydration, elasticity and/or texture of the skin. The compositions can be based on crosslinked hyaluronic acid matrices made with low molecular weight hyaluronic acids.

Abstract: Film forming compositions and methods for preventing stains and increasing shine and gloss of teeth. The film forming compositions may include a polymer, such as a hydrophobic polymer, and an orally acceptable solvent. The hydrophobic polymer may include an acrylate component and a hydrophobic group coupled with one another. The hydrophobic group may include an alkyl chain, a polyethylene glycol, a polypropylene, a polyester, a polyorthoester, a phospholipid, a long chain fatty acid, a vinyl chloride, fluorethylene, a siloxane, a urethane, an octylacrylamide, a butylaminoethyl, a styrene, and combinations thereof.

Abstract: The invention relates to an eyelash coating compositions comprising water, at least one polyelectrolytic compound, at least one film-forming agent, at least two waxes, and an emulsification system comprising low HLB emulsifier(s) (HLB value less than 8) and high HLB emulsifier(s) (HLB value greater than 16), as well as to methods of using such compositions.

Abstract: The present disclosure generally relates to approaches for improving water absorption and retention by the skin's surface. In particular, the disclosure provides compositions and methods for preparing mixtures comprised of ethoxylated oils and water or mixtures comprised of micro or nano emulsions and water, which provide enhanced skin hydration or moisturization to a subject.

Abstract: Compositions disclosed include pearlescent pigment, talc, boron nitride, and a lipid portion. The lipid portion includes a polydialkylsiloxane, a silicone wax, and a diester of a dicarboxylic acid and a fatty alcohol. The composition is substantially free of water. The composition is generally in the form of a pressed-powder. Methods of use are also disclosed.

Abstract: Compositions for reducing skin aging resulting from oxidative stress and/or photodamage are disclosed herein. The compositions can be topically applied to a skin region to reduce or prevent skin wrinkles, fine lines, thinning skin, sagging skin, skin dryness, and skin itchiness.

Abstract: A novel cosmetic complex for bioactive hydration of the skin, particularly from the body and face, is provided. The cosmetic complex comprises vegetable oil, trehalose, and hydroxyethyl urea.

Abstract: Provided are: a method for producing an oral composition suitable for treatment or prevention of a disease or symptom in the oral cavity; and an oral composition produced by the production method. The oral composition production method characterized by including a mixing step of mixing earthworm castings with water and a collecting step of collecting vaporized water generated from a mixture obtained in the mixing step to obtain a liquid; and the oral composition produced by the production method. It is preferred to further mix an organic substance together with the earthworm castings and the water in the mixing step.

Abstract: The present disclosure provides topical compositions of rofecoxib and methods of making said compositions. The present disclosure also provides methods of using topical compositions of rofecoxib to treat inflammation.

Abstract: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble in both water and a volatile organic solvent, yet the carbohydrate-glass particles are insoluble in the volatile organic solvent.

Abstract: An in situ gelling composition comprising nanoparticles comprising soy protein and a bioactive agent, and a sodium alginate film, wherein the nanoparticles are encapsulated in the film. The in situ gelling composition maybe incorporated into a solid dosage form or reconstituted with water for oral administration to a subject in need of sustained release of the bioactive agent.

Abstract: Ready to use liquid formulations of diclofenac potassium are disclosed which are particularly well suited for packaging in stick-packs.

Abstract: Provided herein is a formulation to pre-treat an organ prior to transplantation, comprising a therapeutically effective amount of an immunosuppressive agent encapsulated in a micelle, liposome or polymeric nanoparticle that comprises on its surface a targeting moiety.

Abstract: Disclosed herein are pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. The pharmaceutical formulations are stable and ready-to-use liposomes for the treatment of emesis and are particularly useful for treatment of chemotherapy or surgery-induced nausea and vomiting. Methods of preparation of the aprepitant formulations are also provided.

Abstract: The present disclosure relates to methods of preventing or treating parasite infection in a plurality of fish in need thereof, comprising administering to the fish an effective amount of a medicated fish feed. The medicated fish feed comprises fish feed granules or pellets coated with a composition comprising a neonicotinoid such as imidacloprid and a carrier having a high apparent digestibility coefficient such as a processed/cooked corn protein concentrate.

Abstract: An oral tablet for delivery of active ingredients to the gastrointestinal tract includes a population of particles and an active ingredient to be delivered to the gastrointestinal tract. The population of particles includes directly compressible (DC) and non-directly compressible (non-DC) sugar alcohol particles, the non-DC particles providing the tablet with a plurality of discrete non-DC areas, and the non-DC areas resulting in induced saliva generation upon mastication of the tablet, wherein the tablet is designed to be masticated and designed to deliver the active ingredient to the gastrointestinal tract as part of the saliva generated upon mastication of the tablet.

Abstract: The present invention relates to a protein particle with a poorly water-soluble drug encapsulated therein and a preparation method therefor. The preparation method comprises the following steps: i) dissolving a poorly water-soluble drug and a liquid solubilizer into a good solvent; ii) partially or fully removing said good solvent from the product of step i); iii) mixing the product of step ii) with a protein; and iv) dispersing the product of step iii) in a poor solvent. The preparation method is simple and is suitable for industrial production.

Abstract: A nano drug delivery system includes a biofilm-coated drug nanocrystal. A drug in a physical form of nanocrystal is directly used as a rigid supporting skeleton, and is filled in a biofilm. The nano drug delivery system has the advantages of high drug loading capacity, good biocompatibility, long systemic circulation time and drug sustained release.

Abstract: Some embodiments pertain to nanoparticle-based compositions and their use in methods for the delivery of CBD to subjects. In some embodiments, the compositions are stable for prolonged periods of time and provide enhanced bioavailability.

Abstract: Niclosamide derivatives are provided in the present invention. More particularly, the methods of using niclosamide derivatives for the manufacture of medicaments for suppressing platelet aggregation and preventing thrombosis-related diseases are provided. The niclosamide derivatives in the medicaments inhibit the production of thromboxane A2, therefore suppress platelet aggregation and prevent thrombosis-related diseases.

Abstract: The invention is directed to a topical composition comprising one or more topical active ingredients, one or more nonionic surfactants and one or more viscosity enhancers. The invention is further directed to a method of treating topical conditions comprising applying a composition of the present invention to a subject in need thereof.

Abstract: A positron emission tomography (PET) radiotracer for imaging lactate uptake, wherein the tracer is [18F]-3-fluoro-2-hydroxypropionic acid, or a pharmaceutical acceptable salt and/or solvate thereof. Also, a process for the radiosynthesis of [18F]-3-fluoro-2-hydroxypropionic acid, or a pharmaceutical acceptable salt and/or solvate thereof. Further, the use of [18F]-3-fluoro-2-hydroxypropionic acid, or a pharmaceutical acceptable salt and/or solvate thereof, for imaging lactate uptake in living cells, especially in humans.

Abstract: Exemplary embodiments provide oat fractions, and methods of producing the oat fractions, of the species Avena Sativa that has a concentration of total Avenanthramides that is from about 2 to about 25 wt. %, and up to about 30 wt. % or more, higher than the concentration before treatment with infrared energy. The higher concentration is achieved without treatment with enzymes or exposure to fungal agents to increase the concentration of total Avenanthramides. Instead, the enhanced concentration of Avenanthramides is achieved through exposure to infrared energy for a selected period of time.

Abstract: The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.

Abstract: Improved methods of causing vasodilation in a human subject are disclosed. In one implementation, the human subject is administered a dose of a nitrate salt of arginine, norvaline, or ornithine, wherein the dose of the nitrate salt of the amino acid in moles of the amino acid is less than a molar amount of the amino acid needed to cause vasodilation in the human subject. In another implementation, the human subject is administered a composition comprising a dose of a nitrate salt and an amount of an amino acid, wherein the dose of the nitrate salt in the composition in moles of the nitrate salt is less than a molar amount of the nitrate salt that needs be administered alone in order to induce vasodilation in the human subject. The amino acid in the composition is selected from the group consisting of: arginine, citrulline, creatine, glutamine, leucine, norvaline, and ornithine.

Abstract: The present disclosure relates generally to peroxyformic acid forming compositions and methods for forming peroxyformic acid, preferably in situ, and peroxyformic acid formed by said compositions and methods for the purpose of treating an animal tissue and providing an antimicrobial function thereon. present disclosure in particular relates to a residue-free teat treatment composition for the treatment of an animal tissue, especially bovine teats, which provides antimicrobial efficacy and does not leave a non-food ingredient residue on treated teats.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester in combination with G-CSF or in combination with EPO, are provided for the treatment of cytopenia in mammalian subjects. The compositions and methods also reduce the duration of cytopenia such as neutropenia, thrombocytopenia, and/or anemia.

Abstract: A pharmaceutical combination comprising (A): a polyunsaturated fatty acid and (B): a chemotherapeutic agent compound for the simultaneous, separate or sequential use in the treatment of a cancer in a human patient.

Abstract: This disclosure provides compositions and method useful for treating cell proliferative disorders including cancer. The disclosure provides cannabidiol derivatives and compositions thereof either alone or in combination with THC or a derivative thereof.

Abstract: Described are methods of modulating the activation of the TRPV1 ion channel by administering at least one cannabinoid and/or terpene compound.

Abstract: This invention describes a new method to maximize the epigallocatechin gallate (EGCG) content of brewed tea made using leaves and buds from C. sinensis. Unlike conventional tea processing methods, the method of the invention aims to minimize the leaf withering step, the oxidation step and any heating steps, all of which are present in many conventional tea processing methods. The method of the invention treats minimally withered tea leaf and bud material with an acid treatment and then a maceration treatment, optionally freezing the acid-treated material for storage purposes. The brewed tea resulting from the acid-treated and macerated leaves has a significantly higher EGCG content than conventionally produced teas.

Abstract: Stereomerically pure (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, substantially free of its (?) isomer, and prodrugs, metabolites, polymorphs, salts, solvates, hydrates, and clathrates thereof are discussed. Also discussed are methods of using and pharmaceutical compositions comprising the (+) enantiomer of 2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-? or the inhibition of PDE4.